Although an additive effect of SGLT2i and GLP-1-RA in reducing cardiovascular outcomes has not yet been proved, this panel considered that, if further improvement of blood glucose control is needed, adding a GLP-1RA may be plausible and interesting in T2DM patients with HF. The gene discussed is GLP1R; the disease is hydrops fetalis.